Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics (AXSM) to $212 from $195 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q4 report. The firm believes the Axsome “growth story is not only still in its very early stages, but also, it is still widely underestimated.” It keeps the stock as a top pick.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Buy Rating for Axsome Therapeutics Driven by Promising SYMBRAVO Phase 3 Trial Results
- Axsome Therapeutics’ Symbravo: A Promising Alternative in the Migraine Treatment Market
- Axsome Therapeutics says SYMBRAVO achieves primary endpoint in EMERGE trial
- Optimistic Long-Term Prospects for Axsome Therapeutics Amid Strong Sales and Strategic Pipeline Developments
- Axsome Therapeutics: Strong Commercial Performance and Strategic Growth Initiatives Drive Buy Rating